Next Article in Journal
Development of an Instrument Evaluating the Impact of Surgeon-Patient Relationship in Patients on Sick Leave
Previous Article in Journal
Analysis of Health Economics Assessment Reports for Pharmaceuticals in France—Understanding the Underlying Philosophy of CEESP Assessment
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JMAHP
Volume 5
Issue 1
10.1080/20016689.2017.1345580
jmahp-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Patient Access to Reimbursed Biological Disease-Modifying Antirheumatic Drugs in the European Region

by
Zoltán Kaló
1,
Zoltán Vokó
1,
Andrew Östör
2,
Emma Clifton-Brown
3,
Radu Vasilescu
3,
Alysia Battersby
4 and
Edward Gibson
4,*
1
Department of Health Policy and Health Economics, Eötvös Loránd University, Budapest, Hungary
2
Rheumatology Clinical Research Unit, Addenbrookes Hospital, Cambridge, UK
3
Global Health & Value, Pfizer Ltd, Tadworth, UK
4
Wickenstones Ltd, Chalkwood House, Cold Harbour, Goring Heath, Oxfordshire RG8 7SZ, UK
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2017, 5(1), 1345580; https://doi.org/10.1080/20016689.2017.1345580
Submission received: 17 March 2017 / Revised: 1 January 2017 / Accepted: 19 June 2017 / Published: 5 July 2017

Abstract

Background & Objectives: Biological disease-modifying antirheumatic drugs (bDMARDs) for the treatment of rheumatoid arthritis (RA) are not always accessible to all patients in accordance with international guidelines, partly owing to their high direct costs against a background of restricted healthcare budgets. This study compares the size of RA patient populations with access to reimbursed bDMARDs across 37 European countries, Russia, and Turkey, according to their treatment eligibility defined by European League Against Rheumatism (EULAR) recommendations and national reimbursement criteria. Methods: The size of the RA patient population eligible for bDMARD treatment was estimated in a population model using published RA epidemiological data and clinical criteria defined by 2013 EULAR recommendations along with national reimbursement criteria defined in a survey of the 39 countries in November 2015. Results: According to EULAR recommendations, 32% of the total RA population in the European region is eligible for bDMARD treatment. However, only an average 59% of this EULAR-eligible population remains eligible after applying national reimbursement criteria (from 86% in ‘high access’ to 13% in ‘low-access’ countries). Conclusion: Access to reimbursed bDMARDs remains unequal in the European region. As biosimilars of bDMARDs are introduced, changes in reimbursement criteria may increase access to bDMARDs and reduce this inequality.
Keywords: biological disease-modifying antirheumatic drugs (bDMARDs); rheumatoid arthritis; reimbursement; biosimilars biological disease-modifying antirheumatic drugs (bDMARDs); rheumatoid arthritis; reimbursement; biosimilars

Share and Cite

MDPI and ACS Style

Kaló, Z.; Vokó, Z.; Östör, A.; Clifton-Brown, E.; Vasilescu, R.; Battersby, A.; Gibson, E. Patient Access to Reimbursed Biological Disease-Modifying Antirheumatic Drugs in the European Region. J. Mark. Access Health Policy 2017, 5, 1345580. https://doi.org/10.1080/20016689.2017.1345580

AMA Style

Kaló Z, Vokó Z, Östör A, Clifton-Brown E, Vasilescu R, Battersby A, Gibson E. Patient Access to Reimbursed Biological Disease-Modifying Antirheumatic Drugs in the European Region. Journal of Market Access & Health Policy. 2017; 5(1):1345580. https://doi.org/10.1080/20016689.2017.1345580

Chicago/Turabian Style

Kaló, Zoltán, Zoltán Vokó, Andrew Östör, Emma Clifton-Brown, Radu Vasilescu, Alysia Battersby, and Edward Gibson. 2017. "Patient Access to Reimbursed Biological Disease-Modifying Antirheumatic Drugs in the European Region" Journal of Market Access & Health Policy 5, no. 1: 1345580. https://doi.org/10.1080/20016689.2017.1345580

APA Style

Kaló, Z., Vokó, Z., Östör, A., Clifton-Brown, E., Vasilescu, R., Battersby, A., & Gibson, E. (2017). Patient Access to Reimbursed Biological Disease-Modifying Antirheumatic Drugs in the European Region. Journal of Market Access & Health Policy, 5(1), 1345580. https://doi.org/10.1080/20016689.2017.1345580

Article Metrics

Back to TopTop